TIZIANA LIFE SCIENCES LTD

Insider buying of Tiziana Life Sciences shares signals confidence in its biotech pipeline for autoimmune and liver cancers—yet investors face high risk and weak fundamentals.

CEO Ivor Elrifi buys 667,000 Tiziana Life Sciences shares, signaling confidence in its intranasal foralumab pipeline and potential upside for investors.

Insider buying of Tiziana Life Sciences shares signals confidence in its intranasal foralumab pipeline, hinting at upside for long‑term investors.

Insider CFO keeps options, signaling confidence in Tiziana Life Sciences’ Phase 2a data and future upside.

Discover how insider activity at Tiziana Life Sciences signals confidence in its pipeline while weighing dilution risks, FDA milestones, and payer strategies for investors.